Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): randomized, placebo-controlled, double-blind, phase III clinical trials.

Engensis (donaperminogene seltoplasmid) - Beijing Northland, Reyon Pharma, Helixmith

http://www.ncbi.nlm.nih.gov/pubmed/36002048

Aug 25, 2022